Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + nedaplatin
- Development stage
- Unknown
- Lead developer
- Yakult Honsha
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Irinotecan + nedaplatin is a chemotherapy combination regimen that has been studied for treating various types of cancer. Irinotecan is a topoisomerase I inhibitor, while nedaplatin is a platinum-based antineoplastic agent similar to cisplatin but with potentially reduced toxicity. This combination has shown efficacy in treating primary advanced and recurrent cervical cancer, advanced germ cell tumors, and clear cell carcinoma. In clinical trials, it has demonstrated response rates of up to 81% in primary advanced cervical cancer and 40% in recurrent disease, with manageable toxicity profiles.
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + nedaplatin.